View ValuationPro-Dex 향후 성장Future 기준 점검 0/6Pro-Dex 의 수익은 연간 20.3% 감소할 것으로 예상되는 반면, 연간 수익은 6.4% 로 증가할 것으로 예상됩니다. EPS는 연간 24.7% 만큼 쇠퇴할 것으로 예상됩니다.핵심 정보-20.3%이익 성장률-24.71%EPS 성장률Medical Equipment 이익 성장11.9%매출 성장률6.4%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트12 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • Aug 05Investor sentiment improves as stock rises 21%After last week's 21% share price gain to €59.00, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 18x in the Medical Equipment industry in Germany. Total returns to shareholders of 286% over the past three years.New Risk • Jul 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 20% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Large one-off items impacting financial results.Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. Director Angel Domingo was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공고 • Feb 13Pro-Dex, Inc. (NasdaqCM:PDEX) acquired Advanced Precision Machining Inc. from Sean McCaig and Yasumi McCaig for $8.5 million.Pro-Dex, Inc. (NasdaqCM:PDEX) acquired Advanced Precision Machining Inc. from Sean McCaig and Yasumi McCaig for $8.5 million on February 9, 2026. The APM Interests will be purchased by Pro-Dex for an aggregate amount of $8.65 million subject to any adjustment p, less (x) $39,680 (as the Seller R&W Insurance Amount), and (y) $62,500 (as the Breakup Fee Amount). The Purchase Price shall be paid as follows: (i)at the Closing, Purchaser shall issue a promissory note, in favor of Seller, in the amount of $2 million (the “Note”), which is subordinated to Purchaser’s indebtedness to UMB Bank, N.A., a division of UMB Bank, N.A., successor-in-interest to Minnesota Bank & Trust, a division of HTLF Bank, pursuant to that certain Subordination Agreement, dated as of the date hereof, by and between Seller and the Senior Lender (the “Subordination Agreement”); and (ii)the remaining balance of the Purchase Price (equal to $6,547,820) shall be paid at Closing to the Seller in accordance with the wire instructions provided by the Seller Representative to the Purchaser prior to the Closing Date. In case of termination of transaction, Pro-Dex, Inc. will pay a termination fee of $0.06 million. In connection with the Acquisition, Pro-Dex, Inc. also agreed to engage Sean McCaig as a consultant to provide APM with various consulting services through the end of calendar 2026. Garett Sleichter of Rutan & Tucker acted as legal advisor for Pro-Dex, Inc. David L. Gibbs of The Gibbs Law Firm acted as legal advisor for Advanced Precision Machining Inc. Pro-Dex, Inc. (NasdaqCM:PDEX) completed the acquisition of Advanced Precision Machining Inc. from Sean McCaig and Yasumi McCaig on February 9, 2026.공고 • Oct 08Pro-Dex, Inc., Annual General Meeting, Nov 20, 2025Pro-Dex, Inc., Annual General Meeting, Nov 20, 2025. Location: 2361 mcgavv avenue, irvine, california, United StatesValuation Update With 7 Day Price Move • Nov 07Investor sentiment improves as stock rises 42%After last week's 42% share price gain to €39.40, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total returns to shareholders of 88% over the past three years.Reported Earnings • Nov 01First quarter 2025 earnings released: EPS: US$0.76 (vs US$0.17 loss in 1Q 2024)First quarter 2025 results: EPS: US$0.76 (up from US$0.17 loss in 1Q 2024). Revenue: US$14.9m (up 25% from 1Q 2024). Net income: US$2.47m (up US$3.08m from 1Q 2024). Profit margin: 17% (up from net loss in 1Q 2024). The move to profitability was primarily driven by higher revenue. Revenue is expected to decline by 1.2% p.a. on average during the next 2 years, while revenues in the Medical Equipment industry in Germany are expected to grow by 6.1%. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.공고 • Oct 09Pro-Dex, Inc., Annual General Meeting, Nov 21, 2024Pro-Dex, Inc., Annual General Meeting, Nov 21, 2024. Location: 2361 mcgaw avenue, california, irvine United StatesValuation Update With 7 Day Price Move • Oct 02Investor sentiment improves as stock rises 19%After last week's 19% share price gain to €27.80, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 26x in the Medical Equipment industry in Germany. Total returns to shareholders of 32% over the past three years.Valuation Update With 7 Day Price Move • Sep 12Investor sentiment improves as stock rises 21%After last week's 21% share price gain to €23.60, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total returns to shareholders of 10% over the past three years.Reported Earnings • Sep 06Third quarter 2024 earnings released: EPS: US$0.19 (vs US$0.46 in 3Q 2023)Third quarter 2024 results: EPS: US$0.19 (down from US$0.46 in 3Q 2023). Revenue: US$14.3m (up 9.3% from 3Q 2023). Net income: US$655.0k (down 60% from 3Q 2023). Profit margin: 4.6% (down from 12% in 3Q 2023). Revenue is forecast to grow 2.7% p.a. on average during the next 2 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.New Risk • Sep 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.1% net profit margin). Market cap is less than US$100m (€68.5m market cap, or US$76.1m).Reported Earnings • May 03Third quarter 2024 earnings released: EPS: US$0.19 (vs US$0.37 in 3Q 2023)Third quarter 2024 results: EPS: US$0.19 (down from US$0.37 in 3Q 2023). Revenue: US$14.3m (up 9.3% from 3Q 2023). Net income: US$655.0k (down 50% from 3Q 2023). Profit margin: 4.6% (down from 10.0% in 3Q 2023). Revenue is forecast to grow 2.9% p.a. on average during the next 2 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.Board Change • Apr 04Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 1 experienced director. 5 highly experienced directors. Director Angel Domingo was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.New Risk • Feb 11New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 32% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.2% net profit margin). Market cap is less than US$100m (€60.5m market cap, or US$65.3m).Reported Earnings • Feb 09Second quarter 2024 earnings released: EPS: US$0.14 (vs US$0.25 in 2Q 2023)Second quarter 2024 results: EPS: US$0.14 (down from US$0.25 in 2Q 2023). Revenue: US$12.6m (up 12% from 2Q 2023). Net income: US$500.0k (down 43% from 2Q 2023). Profit margin: 4.0% (down from 7.8% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.8% p.a. on average during the next 2 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 4% per year and the company’s share price has also fallen by 4% per year.Valuation Update With 7 Day Price Move • Jan 11Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €18.00, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total loss to shareholders of 22% over the past three years.공고 • Oct 28Pro-Dex, Inc., Annual General Meeting, Dec 14, 2023Pro-Dex, Inc., Annual General Meeting, Dec 14, 2023, at 09:30 Pacific Standard Time. Location: 14401 Franklin Avenue Tustin California United States Agenda: To elect seven directors to serve until our 2024 annual meeting of shareholders or until their successors are duly elected and qualified; to ratify the appointment of Moss Adams, LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2024; to amend the 2014 Employee Stock Purchase Plan in order to extend its term for an additional ten years; to hold an advisory vote to approve the compensation of our Named Executive Officers; and to transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.공고 • Oct 01Pro-Dex, Inc. announced delayed annual 10-K filingOn 09/29/2023, Pro-Dex, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.Valuation Update With 7 Day Price Move • May 23Investor sentiment improves as stock rises 19%After last week's 19% share price gain to €16.60, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 26x in the Medical Equipment industry in Europe. Total returns to shareholders of 1.8% over the past three years.Reported Earnings • May 08Third quarter 2023 earnings released: EPS: US$0.37 (vs US$0.13 in 3Q 2022)Third quarter 2023 results: EPS: US$0.37 (up from US$0.13 in 3Q 2022). Revenue: US$13.1m (up 41% from 3Q 2022). Net income: US$1.31m (up 184% from 3Q 2022). Profit margin: 10.0% (up from 5.0% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is expected to decline by 2.4% p.a. on average during the next 2 years, while revenues in the Medical Equipment industry in Germany are expected to grow by 6.5%. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.Reported Earnings • Feb 05Second quarter 2023 earnings released: EPS: US$0.25 (vs US$0.25 in 2Q 2022)Second quarter 2023 results: EPS: US$0.25 (down from US$0.25 in 2Q 2022). Revenue: US$11.3m (up 11% from 2Q 2022). Net income: US$879.0k (down 5.0% from 2Q 2022). Profit margin: 7.8% (down from 9.1% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.3% p.a. on average during the next 2 years, compared to a 5.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.공고 • Nov 19Pro-Dex, Inc. Announces Board ElectionsPro-Dex, Inc. announced at annual general meeting held on November 17, 2022, the shareholders elected Angelita R. Domingo and Katrina M.K. Philp to serve as members of the board of directors.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. CEO & Director Rick Van Kirk was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Nov 10Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €15.70, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total returns to shareholders of 37% over the past three years.Reported Earnings • Nov 05First quarter 2023 earnings released: EPS: US$0.30 (vs US$0.29 in 1Q 2022)First quarter 2023 results: EPS: US$0.30 (up from US$0.29 in 1Q 2022). Revenue: US$11.1m (up 11% from 1Q 2022). Net income: US$1.08m (up 1.1% from 1Q 2022). Profit margin: 9.7% (down from 11% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.5% p.a. on average during the next 2 years, compared to a 5.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.Board Change • Oct 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. CEO & Director Rick Van Kirk was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공고 • Oct 04Pro-Dex, Inc., Annual General Meeting, Nov 17, 2022Pro-Dex, Inc., Annual General Meeting, Nov 17, 2022, at 09:30 Pacific Standard Time. Location: headquarters, 2361 McGaw Avenue, Irvine California United States Agenda: To elect seven directors to serve until our 2023 annual meeting of shareholders or until their successors are duly elected and qualified. The nominees for election to Board of Directors are named in the attached Proxy Statement, which is part of this Notice; to ratify the appointment of Moss Adams, LLP as independent registered public accounting firm for the fiscal year ending June 30, 2023; to hold an advisory vote to approve the compensation of Named Executive Officers; and to transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.Valuation Update With 7 Day Price Move • Sep 24Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €15.80, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total returns to shareholders of 16% over the past three years.Reported Earnings • Aug 27Full year 2022 earnings released: EPS: US$1.06 (vs US$1.17 in FY 2021)Full year 2022 results: EPS: US$1.06 (down from US$1.17 in FY 2021). Revenue: US$42.0m (up 11% from FY 2021). Net income: US$3.86m (down 13% from FY 2021). Profit margin: 9.2% (down from 12% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is expected to shrink by 4.9% compared to a 8.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.Recent Insider Transactions • May 13Independent Director recently bought €55k worth of stockOn the 10th of May, Katrina Philp bought around 4k shares on-market at roughly €14.22 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €148k more in shares than they have sold in the last 12 months.Reported Earnings • May 07Third quarter 2022 earnings released: EPS: US$0.13 (vs US$0.52 in 3Q 2021)Third quarter 2022 results: EPS: US$0.13 (down from US$0.52 in 3Q 2021). Revenue: US$9.27m (down 21% from 3Q 2021). Net income: US$462.0k (down 77% from 3Q 2021). Profit margin: 5.0% (down from 17% in 3Q 2021). Over the next year, revenue is forecast to grow 6.9%, compared to a 7.0% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Mar 05Investor sentiment improved over the past weekAfter last week's 15% share price gain to €16.60, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 33x in the Medical Equipment industry in Germany. Total returns to shareholders of 31% over the past three years.Reported Earnings • Feb 04Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatSecond quarter 2022 results: EPS: US$0.25 (up from US$0.087 in 2Q 2021). Revenue: US$10.2m (up 23% from 2Q 2021). Net income: US$925.0k (up 175% from 2Q 2021). Profit margin: 9.1% (up from 4.1% in 2Q 2021). Revenue exceeded analyst estimates by 23%. Over the next year, revenue is forecast to stay flat compared to a 14% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year and the company’s share price has also increased by 17% per year.Reported Earnings • Nov 16First quarter 2022 earnings released: EPS US$0.29 (vs US$0.33 in 1Q 2021)The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2022 results: Revenue: US$9.99m (up 16% from 1Q 2021). Net income: US$1.06m (down 16% from 1Q 2021). Profit margin: 11% (down from 15% in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.Recent Insider Transactions • Sep 15Independent Director recently bought €72k worth of stockOn the 13th of September, Katrina Philp bought around 3k shares on-market at roughly €20.68 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold €339k more in shares than they bought in the last 12 months.Valuation Update With 7 Day Price Move • Sep 02Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to €20.80, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 48x in the Medical Equipment industry in Germany. Total returns to shareholders of 147% over the past three years.Reported Earnings • Aug 28Full year 2021 earnings released: EPS US$1.17 (vs US$1.56 in FY 2020)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2021 results: Revenue: US$38.0m (up 9.2% from FY 2020). Net income: US$4.45m (down 27% from FY 2020). Profit margin: 12% (down from 18% in FY 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has increased by 61% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • May 09Third quarter 2021 earnings released: EPS US$0.52 (vs US$0.31 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$11.7m (up 38% from 3Q 2020). Net income: US$2.00m (up 65% from 3Q 2020). Profit margin: 17% (up from 14% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has increased by 71% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • May 07Investor sentiment improved over the past weekAfter last week's 28% share price gain to US$29.00, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 48x in the Medical Equipment industry in Germany. Total returns to shareholders of 399% over the past three years.Valuation Update With 7 Day Price Move • Mar 26Investor sentiment improved over the past weekAfter last week's 20% share price gain to US$22.40, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 51x in the Medical Equipment industry in Germany. Total returns to shareholders of 302% over the past three years.Valuation Update With 7 Day Price Move • Mar 06Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to US$18.10, the stock is trading at a trailing P/E ratio of 16.4x, down from the previous P/E ratio of 19.5x. This compares to an average P/E of 49x in the Medical Equipment industry in Germany. Total returns to shareholders over the past three years are 227%.Is New 90 Day High Low • Feb 25New 90-day low: €19.90The company is down 40% from its price of €33.00 on 27 November 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 20% over the same period.Recent Insider Transactions • Feb 13Independent Director recently sold €54k worth of stockOn the 12th of February, William Farrell sold around 3k shares on-market at roughly €21.75 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €422k more than they bought in the last 12 months.Valuation Update With 7 Day Price Move • Feb 11Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to US$21.80, the stock is trading at a trailing P/E ratio of 19x, down from the previous P/E ratio of 22.5x. This compares to an average P/E of 54x in the Medical Equipment industry in Germany. Total returns to shareholders over the past three years are 290%.Reported Earnings • Feb 07Second quarter 2021 earnings released: EPS US$0.087 (vs US$0.32 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: US$8.27m (up 3.8% from 2Q 2020). Net income: US$337.0k (down 73% from 2Q 2020). Profit margin: 4.1% (down from 16% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has increased by 59% per year, which means it is tracking significantly ahead of earnings growth.Analyst Estimate Surprise Post Earnings • Feb 07Revenue misses expectationsRevenue missed analyst estimates by 7.3%. Over the next year, revenue is forecast to grow 7.0%, compared to a 14% growth forecast for the Medical Equipment industry in Germany.Is New 90 Day High Low • Feb 06New 90-day low: €22.00The company is down 23% from its price of €28.60 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 23% over the same period.Valuation Update With 7 Day Price Move • Dec 29Investor sentiment deteriorated over the past weekAfter last week's 24% share price decline to US$26.00, the stock is trading at a trailing P/E ratio of 19.5x, down from the previous P/E ratio of 25.7x. This compares to an average P/E of 44x in the Medical Equipment industry in Germany. Total returns to shareholders over the past three years are 356%.Is New 90 Day High Low • Dec 18New 90-day high: €33.20The company is up 34% from its price of €24.80 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period.Is New 90 Day High Low • Nov 13New 90-day high: €32.80The company is up 82% from its price of €18.00 on 14 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 7.0% over the same period.Recent Insider Transactions • Nov 13Independent Director recently sold €88k worth of stockOn the 10th of November, William Farrell sold around 3k shares on-market at roughly €31.45 per share. In the last 3 months, there was an even bigger sale from another insider worth €242k. Insiders have been net sellers, collectively disposing of €409k more than they bought in the last 12 months.Reported Earnings • Nov 07First quarter 2021 earnings released: EPS US$0.33The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: US$8.59m (up 19% from 1Q 2020). Net income: US$1.27m (up 15% from 1Q 2020). Profit margin: 15% (in line with 1Q 2020). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 65% per year, which means it is tracking significantly ahead of earnings growth.Analyst Estimate Surprise Post Earnings • Nov 07Revenue beats expectationsRevenue exceeded analyst estimates by 3.2%. Over the next year, revenue is forecast to grow 6.5%, compared to a 13% growth forecast for the Medical Equipment industry in Germany.Is New 90 Day High Low • Oct 21New 90-day high: €28.00The company is up 76% from its price of €15.90 on 22 July 2020. The German market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is flat over the same period.Valuation Update With 7 Day Price Move • Oct 21Market bids up stock over the past weekAfter last week's 20% share price gain to US$28.00, the stock is trading at a trailing P/E ratio of 17.5x, up from the previous P/E ratio of 14.6x. This compares to an average P/E of 53x in the Medical Equipment industry in Germany. Total returns to shareholders over the past three years are 328%.Recent Insider Transactions • Sep 26CEO, President recently sold €242k worth of stockOn the 23rd of September, Richard Van Kirk sold around 10k shares on-market at roughly €23.53 per share. This was the largest sale by an insider in the last 3 months. This was Richard's only on-market trade for the last 12 months.이익 및 매출 성장 예측DB:PDXN - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수6/30/20278110N/A916/30/20267613N/A1213/31/2026751277N/A12/31/2025721166N/A9/30/20257011-2-1N/A6/30/2025679-3-2N/A3/31/2025649-20N/A12/31/202461723N/A9/30/202457568N/A6/30/202454256N/A3/31/202449256N/A12/31/202348334N/A9/30/202347523N/A6/30/202346745N/A3/31/2023488-20N/A12/31/2022447-4-3N/A9/30/2022435-2-1N/A6/30/2022425-3-1N/A3/31/202239335N/A12/31/2021415-21N/A9/30/2021396-82N/A6/30/2021386-10-2N/A3/31/2021408-80N/A12/31/2020367-43N/A9/30/202036633N/A6/30/202035645N/A3/31/202031423N/A12/31/2019294N/A4N/A9/30/2019274N/A4N/A6/30/2019274N/A3N/A3/31/2019263N/A4N/A12/31/2018253N/A3N/A9/30/2018242N/A3N/A6/30/2018222N/A3N/A3/31/2018222N/A3N/A12/31/2017232N/A4N/A9/30/2017225N/A4N/A6/30/2017225N/A3N/A3/31/2017214N/A3N/A12/31/2016204N/A2N/A9/30/2016202N/A1N/A6/30/2016191N/A0N/A3/31/2016181N/A-1N/A12/31/2015170N/A-1N/A9/30/2015150N/A-2N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: PDXN 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -20.3%).수익 vs 시장: PDXN 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -20.3%).고성장 수익: PDXN 의 수익은 향후 3년간 감소할 것으로 예상됩니다.수익 대 시장: PDXN 의 수익(연간 6.4%)이 German 시장(연간 6.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: PDXN 의 수익(연간 6.4%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: PDXN의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/20 23:17종가2026/08/20 00:00수익2026/03/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Pro-Dex, Inc.는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Edward WooAscendiant Capital Markets LLC
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment improves as stock rises 21%After last week's 21% share price gain to €59.00, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 18x in the Medical Equipment industry in Germany. Total returns to shareholders of 286% over the past three years.
New Risk • Jul 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 20% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Large one-off items impacting financial results.
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. Director Angel Domingo was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공고 • Feb 13Pro-Dex, Inc. (NasdaqCM:PDEX) acquired Advanced Precision Machining Inc. from Sean McCaig and Yasumi McCaig for $8.5 million.Pro-Dex, Inc. (NasdaqCM:PDEX) acquired Advanced Precision Machining Inc. from Sean McCaig and Yasumi McCaig for $8.5 million on February 9, 2026. The APM Interests will be purchased by Pro-Dex for an aggregate amount of $8.65 million subject to any adjustment p, less (x) $39,680 (as the Seller R&W Insurance Amount), and (y) $62,500 (as the Breakup Fee Amount). The Purchase Price shall be paid as follows: (i)at the Closing, Purchaser shall issue a promissory note, in favor of Seller, in the amount of $2 million (the “Note”), which is subordinated to Purchaser’s indebtedness to UMB Bank, N.A., a division of UMB Bank, N.A., successor-in-interest to Minnesota Bank & Trust, a division of HTLF Bank, pursuant to that certain Subordination Agreement, dated as of the date hereof, by and between Seller and the Senior Lender (the “Subordination Agreement”); and (ii)the remaining balance of the Purchase Price (equal to $6,547,820) shall be paid at Closing to the Seller in accordance with the wire instructions provided by the Seller Representative to the Purchaser prior to the Closing Date. In case of termination of transaction, Pro-Dex, Inc. will pay a termination fee of $0.06 million. In connection with the Acquisition, Pro-Dex, Inc. also agreed to engage Sean McCaig as a consultant to provide APM with various consulting services through the end of calendar 2026. Garett Sleichter of Rutan & Tucker acted as legal advisor for Pro-Dex, Inc. David L. Gibbs of The Gibbs Law Firm acted as legal advisor for Advanced Precision Machining Inc. Pro-Dex, Inc. (NasdaqCM:PDEX) completed the acquisition of Advanced Precision Machining Inc. from Sean McCaig and Yasumi McCaig on February 9, 2026.
공고 • Oct 08Pro-Dex, Inc., Annual General Meeting, Nov 20, 2025Pro-Dex, Inc., Annual General Meeting, Nov 20, 2025. Location: 2361 mcgavv avenue, irvine, california, United States
Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improves as stock rises 42%After last week's 42% share price gain to €39.40, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total returns to shareholders of 88% over the past three years.
Reported Earnings • Nov 01First quarter 2025 earnings released: EPS: US$0.76 (vs US$0.17 loss in 1Q 2024)First quarter 2025 results: EPS: US$0.76 (up from US$0.17 loss in 1Q 2024). Revenue: US$14.9m (up 25% from 1Q 2024). Net income: US$2.47m (up US$3.08m from 1Q 2024). Profit margin: 17% (up from net loss in 1Q 2024). The move to profitability was primarily driven by higher revenue. Revenue is expected to decline by 1.2% p.a. on average during the next 2 years, while revenues in the Medical Equipment industry in Germany are expected to grow by 6.1%. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.
공고 • Oct 09Pro-Dex, Inc., Annual General Meeting, Nov 21, 2024Pro-Dex, Inc., Annual General Meeting, Nov 21, 2024. Location: 2361 mcgaw avenue, california, irvine United States
Valuation Update With 7 Day Price Move • Oct 02Investor sentiment improves as stock rises 19%After last week's 19% share price gain to €27.80, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 26x in the Medical Equipment industry in Germany. Total returns to shareholders of 32% over the past three years.
Valuation Update With 7 Day Price Move • Sep 12Investor sentiment improves as stock rises 21%After last week's 21% share price gain to €23.60, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total returns to shareholders of 10% over the past three years.
Reported Earnings • Sep 06Third quarter 2024 earnings released: EPS: US$0.19 (vs US$0.46 in 3Q 2023)Third quarter 2024 results: EPS: US$0.19 (down from US$0.46 in 3Q 2023). Revenue: US$14.3m (up 9.3% from 3Q 2023). Net income: US$655.0k (down 60% from 3Q 2023). Profit margin: 4.6% (down from 12% in 3Q 2023). Revenue is forecast to grow 2.7% p.a. on average during the next 2 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
New Risk • Sep 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.1% net profit margin). Market cap is less than US$100m (€68.5m market cap, or US$76.1m).
Reported Earnings • May 03Third quarter 2024 earnings released: EPS: US$0.19 (vs US$0.37 in 3Q 2023)Third quarter 2024 results: EPS: US$0.19 (down from US$0.37 in 3Q 2023). Revenue: US$14.3m (up 9.3% from 3Q 2023). Net income: US$655.0k (down 50% from 3Q 2023). Profit margin: 4.6% (down from 10.0% in 3Q 2023). Revenue is forecast to grow 2.9% p.a. on average during the next 2 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.
Board Change • Apr 04Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 1 experienced director. 5 highly experienced directors. Director Angel Domingo was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
New Risk • Feb 11New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 32% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.2% net profit margin). Market cap is less than US$100m (€60.5m market cap, or US$65.3m).
Reported Earnings • Feb 09Second quarter 2024 earnings released: EPS: US$0.14 (vs US$0.25 in 2Q 2023)Second quarter 2024 results: EPS: US$0.14 (down from US$0.25 in 2Q 2023). Revenue: US$12.6m (up 12% from 2Q 2023). Net income: US$500.0k (down 43% from 2Q 2023). Profit margin: 4.0% (down from 7.8% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.8% p.a. on average during the next 2 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 4% per year and the company’s share price has also fallen by 4% per year.
Valuation Update With 7 Day Price Move • Jan 11Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €18.00, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total loss to shareholders of 22% over the past three years.
공고 • Oct 28Pro-Dex, Inc., Annual General Meeting, Dec 14, 2023Pro-Dex, Inc., Annual General Meeting, Dec 14, 2023, at 09:30 Pacific Standard Time. Location: 14401 Franklin Avenue Tustin California United States Agenda: To elect seven directors to serve until our 2024 annual meeting of shareholders or until their successors are duly elected and qualified; to ratify the appointment of Moss Adams, LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2024; to amend the 2014 Employee Stock Purchase Plan in order to extend its term for an additional ten years; to hold an advisory vote to approve the compensation of our Named Executive Officers; and to transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
공고 • Oct 01Pro-Dex, Inc. announced delayed annual 10-K filingOn 09/29/2023, Pro-Dex, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
Valuation Update With 7 Day Price Move • May 23Investor sentiment improves as stock rises 19%After last week's 19% share price gain to €16.60, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 26x in the Medical Equipment industry in Europe. Total returns to shareholders of 1.8% over the past three years.
Reported Earnings • May 08Third quarter 2023 earnings released: EPS: US$0.37 (vs US$0.13 in 3Q 2022)Third quarter 2023 results: EPS: US$0.37 (up from US$0.13 in 3Q 2022). Revenue: US$13.1m (up 41% from 3Q 2022). Net income: US$1.31m (up 184% from 3Q 2022). Profit margin: 10.0% (up from 5.0% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is expected to decline by 2.4% p.a. on average during the next 2 years, while revenues in the Medical Equipment industry in Germany are expected to grow by 6.5%. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
Reported Earnings • Feb 05Second quarter 2023 earnings released: EPS: US$0.25 (vs US$0.25 in 2Q 2022)Second quarter 2023 results: EPS: US$0.25 (down from US$0.25 in 2Q 2022). Revenue: US$11.3m (up 11% from 2Q 2022). Net income: US$879.0k (down 5.0% from 2Q 2022). Profit margin: 7.8% (down from 9.1% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.3% p.a. on average during the next 2 years, compared to a 5.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.
공고 • Nov 19Pro-Dex, Inc. Announces Board ElectionsPro-Dex, Inc. announced at annual general meeting held on November 17, 2022, the shareholders elected Angelita R. Domingo and Katrina M.K. Philp to serve as members of the board of directors.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. CEO & Director Rick Van Kirk was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Nov 10Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €15.70, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total returns to shareholders of 37% over the past three years.
Reported Earnings • Nov 05First quarter 2023 earnings released: EPS: US$0.30 (vs US$0.29 in 1Q 2022)First quarter 2023 results: EPS: US$0.30 (up from US$0.29 in 1Q 2022). Revenue: US$11.1m (up 11% from 1Q 2022). Net income: US$1.08m (up 1.1% from 1Q 2022). Profit margin: 9.7% (down from 11% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.5% p.a. on average during the next 2 years, compared to a 5.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.
Board Change • Oct 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. CEO & Director Rick Van Kirk was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공고 • Oct 04Pro-Dex, Inc., Annual General Meeting, Nov 17, 2022Pro-Dex, Inc., Annual General Meeting, Nov 17, 2022, at 09:30 Pacific Standard Time. Location: headquarters, 2361 McGaw Avenue, Irvine California United States Agenda: To elect seven directors to serve until our 2023 annual meeting of shareholders or until their successors are duly elected and qualified. The nominees for election to Board of Directors are named in the attached Proxy Statement, which is part of this Notice; to ratify the appointment of Moss Adams, LLP as independent registered public accounting firm for the fiscal year ending June 30, 2023; to hold an advisory vote to approve the compensation of Named Executive Officers; and to transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
Valuation Update With 7 Day Price Move • Sep 24Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €15.80, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total returns to shareholders of 16% over the past three years.
Reported Earnings • Aug 27Full year 2022 earnings released: EPS: US$1.06 (vs US$1.17 in FY 2021)Full year 2022 results: EPS: US$1.06 (down from US$1.17 in FY 2021). Revenue: US$42.0m (up 11% from FY 2021). Net income: US$3.86m (down 13% from FY 2021). Profit margin: 9.2% (down from 12% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is expected to shrink by 4.9% compared to a 8.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.
Recent Insider Transactions • May 13Independent Director recently bought €55k worth of stockOn the 10th of May, Katrina Philp bought around 4k shares on-market at roughly €14.22 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €148k more in shares than they have sold in the last 12 months.
Reported Earnings • May 07Third quarter 2022 earnings released: EPS: US$0.13 (vs US$0.52 in 3Q 2021)Third quarter 2022 results: EPS: US$0.13 (down from US$0.52 in 3Q 2021). Revenue: US$9.27m (down 21% from 3Q 2021). Net income: US$462.0k (down 77% from 3Q 2021). Profit margin: 5.0% (down from 17% in 3Q 2021). Over the next year, revenue is forecast to grow 6.9%, compared to a 7.0% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Mar 05Investor sentiment improved over the past weekAfter last week's 15% share price gain to €16.60, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 33x in the Medical Equipment industry in Germany. Total returns to shareholders of 31% over the past three years.
Reported Earnings • Feb 04Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatSecond quarter 2022 results: EPS: US$0.25 (up from US$0.087 in 2Q 2021). Revenue: US$10.2m (up 23% from 2Q 2021). Net income: US$925.0k (up 175% from 2Q 2021). Profit margin: 9.1% (up from 4.1% in 2Q 2021). Revenue exceeded analyst estimates by 23%. Over the next year, revenue is forecast to stay flat compared to a 14% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year and the company’s share price has also increased by 17% per year.
Reported Earnings • Nov 16First quarter 2022 earnings released: EPS US$0.29 (vs US$0.33 in 1Q 2021)The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2022 results: Revenue: US$9.99m (up 16% from 1Q 2021). Net income: US$1.06m (down 16% from 1Q 2021). Profit margin: 11% (down from 15% in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.
Recent Insider Transactions • Sep 15Independent Director recently bought €72k worth of stockOn the 13th of September, Katrina Philp bought around 3k shares on-market at roughly €20.68 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold €339k more in shares than they bought in the last 12 months.
Valuation Update With 7 Day Price Move • Sep 02Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to €20.80, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 48x in the Medical Equipment industry in Germany. Total returns to shareholders of 147% over the past three years.
Reported Earnings • Aug 28Full year 2021 earnings released: EPS US$1.17 (vs US$1.56 in FY 2020)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2021 results: Revenue: US$38.0m (up 9.2% from FY 2020). Net income: US$4.45m (down 27% from FY 2020). Profit margin: 12% (down from 18% in FY 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has increased by 61% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • May 09Third quarter 2021 earnings released: EPS US$0.52 (vs US$0.31 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$11.7m (up 38% from 3Q 2020). Net income: US$2.00m (up 65% from 3Q 2020). Profit margin: 17% (up from 14% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has increased by 71% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • May 07Investor sentiment improved over the past weekAfter last week's 28% share price gain to US$29.00, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 48x in the Medical Equipment industry in Germany. Total returns to shareholders of 399% over the past three years.
Valuation Update With 7 Day Price Move • Mar 26Investor sentiment improved over the past weekAfter last week's 20% share price gain to US$22.40, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 51x in the Medical Equipment industry in Germany. Total returns to shareholders of 302% over the past three years.
Valuation Update With 7 Day Price Move • Mar 06Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to US$18.10, the stock is trading at a trailing P/E ratio of 16.4x, down from the previous P/E ratio of 19.5x. This compares to an average P/E of 49x in the Medical Equipment industry in Germany. Total returns to shareholders over the past three years are 227%.
Is New 90 Day High Low • Feb 25New 90-day low: €19.90The company is down 40% from its price of €33.00 on 27 November 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 20% over the same period.
Recent Insider Transactions • Feb 13Independent Director recently sold €54k worth of stockOn the 12th of February, William Farrell sold around 3k shares on-market at roughly €21.75 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €422k more than they bought in the last 12 months.
Valuation Update With 7 Day Price Move • Feb 11Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to US$21.80, the stock is trading at a trailing P/E ratio of 19x, down from the previous P/E ratio of 22.5x. This compares to an average P/E of 54x in the Medical Equipment industry in Germany. Total returns to shareholders over the past three years are 290%.
Reported Earnings • Feb 07Second quarter 2021 earnings released: EPS US$0.087 (vs US$0.32 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: US$8.27m (up 3.8% from 2Q 2020). Net income: US$337.0k (down 73% from 2Q 2020). Profit margin: 4.1% (down from 16% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has increased by 59% per year, which means it is tracking significantly ahead of earnings growth.
Analyst Estimate Surprise Post Earnings • Feb 07Revenue misses expectationsRevenue missed analyst estimates by 7.3%. Over the next year, revenue is forecast to grow 7.0%, compared to a 14% growth forecast for the Medical Equipment industry in Germany.
Is New 90 Day High Low • Feb 06New 90-day low: €22.00The company is down 23% from its price of €28.60 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 23% over the same period.
Valuation Update With 7 Day Price Move • Dec 29Investor sentiment deteriorated over the past weekAfter last week's 24% share price decline to US$26.00, the stock is trading at a trailing P/E ratio of 19.5x, down from the previous P/E ratio of 25.7x. This compares to an average P/E of 44x in the Medical Equipment industry in Germany. Total returns to shareholders over the past three years are 356%.
Is New 90 Day High Low • Dec 18New 90-day high: €33.20The company is up 34% from its price of €24.80 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period.
Is New 90 Day High Low • Nov 13New 90-day high: €32.80The company is up 82% from its price of €18.00 on 14 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 7.0% over the same period.
Recent Insider Transactions • Nov 13Independent Director recently sold €88k worth of stockOn the 10th of November, William Farrell sold around 3k shares on-market at roughly €31.45 per share. In the last 3 months, there was an even bigger sale from another insider worth €242k. Insiders have been net sellers, collectively disposing of €409k more than they bought in the last 12 months.
Reported Earnings • Nov 07First quarter 2021 earnings released: EPS US$0.33The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: US$8.59m (up 19% from 1Q 2020). Net income: US$1.27m (up 15% from 1Q 2020). Profit margin: 15% (in line with 1Q 2020). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 65% per year, which means it is tracking significantly ahead of earnings growth.
Analyst Estimate Surprise Post Earnings • Nov 07Revenue beats expectationsRevenue exceeded analyst estimates by 3.2%. Over the next year, revenue is forecast to grow 6.5%, compared to a 13% growth forecast for the Medical Equipment industry in Germany.
Is New 90 Day High Low • Oct 21New 90-day high: €28.00The company is up 76% from its price of €15.90 on 22 July 2020. The German market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is flat over the same period.
Valuation Update With 7 Day Price Move • Oct 21Market bids up stock over the past weekAfter last week's 20% share price gain to US$28.00, the stock is trading at a trailing P/E ratio of 17.5x, up from the previous P/E ratio of 14.6x. This compares to an average P/E of 53x in the Medical Equipment industry in Germany. Total returns to shareholders over the past three years are 328%.
Recent Insider Transactions • Sep 26CEO, President recently sold €242k worth of stockOn the 23rd of September, Richard Van Kirk sold around 10k shares on-market at roughly €23.53 per share. This was the largest sale by an insider in the last 3 months. This was Richard's only on-market trade for the last 12 months.